Key result
Antiviral antibody therapies offer valuable prevention and treatment for viral diseases despite unique development challenges.
Why the study?
Viral diseases represent a major public health concern and pandemic risk, making antiviral antibody therapeutics valuable options whose properties, characterization, and challenges require review.
This review provides an overview of the development, characterization, and clinical utility of antiviral polyclonal and monoclonal antibody therapies.
Answers are grounded in this paper and cite their sources.
Antibody therapies offer viral disease options; extends synthesis of properties and challenges while leaving optimization for emerging threats unresolved.
Viral diseases represent a major public health concern and an ever-present risk for developing into a future pandemic. Antiviral antibody therapeutics, either alone or in combination with other therapies, have emerged as valuable preventative and treatment options, including during a global emergency. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research.
No takes yet. Share an insight, caveat, or question.
Struble et al. (2023) conducted a review in Viral diseases. Antiviral polyclonal and monoclonal antibody therapies was evaluated. Antiviral polyclonal and monoclonal antibody therapies serve as valuable preventative and treatment options for viral diseases, with unique biochemical properties and development challenges.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: